Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer.
- Author:
Xi LI
1
;
Xin-jie YANG
;
Yi-fen SUN
;
Na QIN
;
Jia-lin LÜ
;
Yu-hua WU
;
Hui ZHANG
;
Quan ZHANG
;
Shu-cai ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; adverse effects; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; genetics; pathology; Crown Ethers; adverse effects; therapeutic use; Diarrhea; chemically induced; Disease Progression; Exanthema; chemically induced; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; drug therapy; genetics; pathology; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; adverse effects; therapeutic use; Receptor, Epidermal Growth Factor; genetics; Remission Induction; Retrospective Studies; Survival Rate
- From: Chinese Journal of Oncology 2012;34(8):627-631
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the efficacy and side effects of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
METHODSThe efficacy and side effects of icotinib hydrochloride in treatment of 59 cases with stage IV NSCIC and followed-up from March 2009 to January 2012 were retrospectively analyzed.
RESULTSTwenty seven patients (45.8%) showed partial response (PR), 17 patients (28.8%) achieved SD, and 15 (25.4%) had progressive disease. The objective response rate (ORR) was 45.8% (27/59), and disease control rate (DCR) was 74.6% (44/59). Among the 23 patients with EGFR mutation, ORR was 73.9% (17/23), and DCR was 95.7% (22/23). Thirty six patients (61.0%) achieved remission of symptoms to varying degrees. The main symptoms relieved were cough, asthmatic suffocating, pain and hoarseness. The major adverse events were mild skin rash (35.6%) and diarrhea (15.3%). Others were dry skin, nausea and stomach problems. The efficacy of icotinib hydrochloride were related to the ECOG performance status, smoking history, EGFR mutation and rash significantly (P < 0.05).
CONCLUSIONSMonotherapy with icotinib hydrochloride is effective and tolerable for patients with advanced NSCLC, especially with EGFR mutation.
